A randomized, controlled pilot study to evaluate the immediate effect of targeted exercise therapy on cancer-related fatigue in cancer survivors – the FatiGO study
Conclusions: This pilot study showed the feasibility of close-meshed daily fatigue screening. Preliminary data indicates that Cancer survivors are able to train in high intensity ranges with tendencies towards decreased fatigue. Therefore, practicability of the study design is shown. Further results are expected within the prospective multicentre trial. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - July 18, 2022 Category: Cancer & Oncology Source Type: research
Awareness of human papillomavirus (HPV) and HPV vaccination amongst the general population in Germany – lack of awareness and need for action
Introduction: The oncogenic human papillomaviruses (HPV) types 16 and 18 contribute to more than 73% cases of all HPV-related cancers and commonly affect the anogenital and head and neck region, with rapidly rising incidence rates of HPV-related oropharyngeal squamous cell carcinomas (OPSCC). HPV vaccination has the potential to decrease the burden of HPV-related disease but vaccination rates remain low in many countries. We investigated the level of awareness of HPV, and HPV-OPSCC in particular, in a representative sample of the German population.
Materials and Methods: As part of an online, population-based survey, an e...
Source: Oncology Research and Treatment - July 18, 2022 Category: Cancer & Oncology Source Type: research
ASCO Annual Meeting 2022: Neue Daten zu Antik örper-Drug-Konjugaten (ADCs) und CDK4/6-Inhibitoren beim metastasierten Mammakarzinom
In der DESTINY-Breast04-Studie zeigte das ADC Trastuzumab-Deruxtecan bei vorbehandelten Patientinnen mit niedriger HER2-Expression eine deutliche Verl ängerung des progressionsfreien Überlebens (PFS) sowie des Gesamtüberlebens (OS) verglichen mit konventioneller Chemotherapie nach Wahl des Behandlers [1]. Positive Ergebnisse gab es auch aus der TROPiCS-02-Studie mit dem ADC Sacituzumab-Govitecan bei Patientinnen mit metastasiertem, hormonresist entem Mammakarzinom [2]. Interessant waren auch die Ergebnisse der MAINTAIN-Studie zur Frage, ob CDK4/6-Inhibitoren bei Patientinnen mit HR+/HER2-negativem metastasiertem Mammaka...
Source: Oncology Research and Treatment - June 28, 2022 Category: Cancer & Oncology Source Type: research
Diagnostic Value of sST2, VCAM-1, and Adiponectin in Patients with Breast Cancer to Predict Anti-Tumour Treatment-Related Cardiac Events: A Pilot Study
Conclusion: Cardiac events during anti-tumour treatment in patients with breast cancer are relatively common. Inflammatory markers such as VCAM-1 or sST2 were associated with an increased likelihood for occurrence of a treatment-related event, which may therefore hold the promise to better identify patients at high risk.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - June 28, 2022 Category: Cancer & Oncology Source Type: research
Diagnostic value of sST2, VCAM-1 and adiponectin in patients with breast cancer to predict anti-tumor treatment-related cardiac events: A pilot study
Conclusion Cardiac events during anti-tumour treatment in patients with breast cancer are relatively common. Inflammatory markers such as VCAM-1 or sST2 were associated with an increased likelihood for occurrence of a treatment-related event, which may therefore hold the promise to better identify patients at high risk. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - June 28, 2022 Category: Cancer & Oncology Source Type: research
A prospective study on defining the indications of prophylactic level IB radiotherapy in nasopharyngeal carcinoma based on a risk score model
Conclusion: Omission of level IB irradiation was feasible for patients with low-risk IB lymph nodes metastasis. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - June 15, 2022 Category: Cancer & Oncology Source Type: research
Sex-Disaggregated Analysis of Biology, Treatment Tolerability, and Outcome of Multiple Myeloma in a German Cohort
Conclusion: In conclusion, this first sex-disaggregated analysis of MM patients in Germany supports previous findings that survival is comparable amongst sexes, but women experience more toxicity of high-dose therapy. The higher incidence of clinically relevant anaemia in women warrants further investigation to exclude underlying treatable causes. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - June 15, 2022 Category: Cancer & Oncology Source Type: research
Sex-disaggregated analysis of biology, treatment tolerability and outcome of Multiple Myeloma in a German cohort
We present sex-disaggregated analysis of the characteristics and outcome of MM in a cohort of 655 patients (median age at diagnosis 62 years; 363 men with a median age at diagnosis 62 years and 292 women with a median age at diagnosis 63 years, p=0.086). Most patients (n=561, 86%) received myeloma-specific treatment. Median overall survival was 76 months (95% CI 63 – 89) (72 months in men [95% CI 54 – 90] and 83 months in women [95% CI 66 – 100], p=ns). Apart from a higher incidence of moderate and severe anaemia in women (p (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - June 15, 2022 Category: Cancer & Oncology Source Type: research
Breast Cancer Patients are at Increased Risk of Developing Uterine Serous Cancer: Implications for Counseling - A SEER analysis
Introduction: Several studies have investigated whether patients with prior breast cancer (BC) are at increased risk for endometrial cancer/uterine serous cancer (USC). We aimed to study this relationship and analyze the effect of prior BC on the incidence and prognosis of USC patients.
Methods: With permission of the Surveillance, Epidemiology and End Results (SEER) program of the United States National Cancer Institute, clinicopathological information of women diagnosed with BC and following USC were analyzed. The recorded data included age at diagnosis, stage of disease, cause of death, interval time between BC and USC...
Source: Oncology Research and Treatment - June 15, 2022 Category: Cancer & Oncology Source Type: research
A systematic review for evaluation of specialized programs for addressing young women with breast cancer problems
Conclusion: Evaluation of the current situation of BC patient’s treatment and quality of life highlighted the importance of developing and implementing the new and m ost efficient healthcare programs and protocols, as well as improving and optimizing the existing ones to improve and enhance the survival rate and quality of life of BC patients.
Keywords: Cancer, Breast cancer, Breast cancer issues, Breast cancer programs. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - June 14, 2022 Category: Cancer & Oncology Source Type: research
Transferability of health-related quality of life data of large observational studies to clinical practice – comparing retroperitoneal sarcoma patients from the PROSa study to a TARPS-WG cohort
Conclusion: Clinical data from RPS-PROSa patients are comparable to those of a RPS reference cohort from expert centers. We be lieve that HRQoL-data of RPS patients extracted from PROSa are transferable to clinical practice. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - June 14, 2022 Category: Cancer & Oncology Source Type: research
Sequential geriatric assessment in older patients with colorectal cancer during chemotherapy —subgroup analysis of a prospective, multi-center study EpiReal 75
Conclusion: Sequential GA revealed changes of FS in older patients with CRC receiving chemotherapy. A deterioration of FS during chemotherapy did not influence PFS but had a negative impact on OS and QoL. It is therefore important to maintain FS in older patients with cancer, and regular performance of geriatric core assessments should be encouraged in the clinical practice. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - June 8, 2022 Category: Cancer & Oncology Source Type: research
Society Bulletins
Oncol Res Treat 2022;45:391 –394 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - June 2, 2022 Category: Cancer & Oncology Source Type: research
PharmaNews
Oncol Res Treat 2022;45:387 –390 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - June 2, 2022 Category: Cancer & Oncology Source Type: research
PharmaNews
Oncol Res Treat 2022;45:384 –386 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - June 2, 2022 Category: Cancer & Oncology Source Type: research
